Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results